A Meta-Analysis of Cognitive Remediation for Schizophrenia: Methodology and Effect Sizes
Publication: American Journal of Psychiatry
Abstract
Objective:
Cognitive remediation therapy for schizophrenia was developed to treat cognitive problems that affect functioning, but the treatment effects may depend on the type of trial methodology adopted. The present meta-analysis will determine the effects of treatment and whether study method or potential moderators influence the estimates.
Method:
Electronic databases were searched up to June 2009 using variants of the key words “cognitive,” “training,” “remediation,” “clinical trial,” and “schizophrenia.” Key researchers were contacted to ensure that all studies meeting the criteria were included. This produced 109 reports of 40 studies in which ≥70% of participants had a diagnosis of schizophrenia, all of whom received standard care. There was a comparison group and allocation procedure in these studies. Data were available to calculate effect sizes on cognition and/or functioning. Data were independently extracted by two reviewers with excellent reliability. Methodological moderators were extracted through the Clinical Trials Assessment Measure and verified by authors in 94% of cases.
Results:
The meta-analysis (2,104 participants) yielded durable effects on global cognition and functioning. The symptom effect was small and disappeared at follow-up assessment. No treatment element (remediation approach, duration, computer use, etc.) was associated with cognitive outcome. Cognitive remediation therapy was more effective when patients were clinically stable. Significantly stronger effects on functioning were found when cognitive remediation therapy was provided together with other psychiatric rehabilitation, and a much larger effect was present when a strategic approach was adopted together with adjunctive rehabilitation. Despite variability in methodological rigor, this did not moderate any of the therapy effects, and even in the most rigorous studies there were similar small-to-moderate effects.
Conclusions:
Cognitive remediation benefits people with schizophrenia, and when combined with psychiatric rehabilitation, this benefit generalizes to functioning, relative to rehabilitation alone. These benefits cannot be attributed to poor study methods.
As defined at the Cognitive Remediation Experts Workshop (Florence, Italy, April 2010), cognitive remediation therapy for schizophrenia is “a behavioral training based intervention that aims to improve cognitive processes (attention, memory, executive function, social cognition or metacognition) with the goal of durability and generalization.” Its development was fueled by a number of studies demonstrating links between cognition and future functioning (1), the effects on rehabilitation outcomes (1–6), and from complaints by service users themselves about the interference with their everyday lives.
A large body of data on the efficacy of cognitive remediation therapy has been produced, and a number of meta-analyses have shown moderate to large effects on cognitive outcomes (7–13). All reviews pointed to variability in cognitive remediation technology, in the target population, and in the targeted outcomes (11, 14). Some have even suggested that methodology might bias the effect estimates and inflate their effects. Previous reviews also have indicated that trials of cognitive remediation have not sufficiently addressed functioning outcomes, since few have involved these measures and even fewer have examined longer-term effects. Following these criticisms, remediation experts have produced a series of studies that address functioning, almost doubling the amount of available studies.
Cognitive remediation therapy aims to enhance cognition with a further goal that improved cognition will affect community functioning. There have been historic concerns about identifying appropriate cognitive targets. Should we choose those that are more malleable or that have the greatest chance of boosting functioning (15)? Previous reviews indicate that nearly all cognitive domains, except visual learning and memory, respond to remediation in the treatment of schizophrenia (e.g., 9), and thus there is no indication of more malleable cognitive targets. Heterogeneity of cognitive difficulties is also well established in schizophrenia (16), and therefore a broader approach that targets multiple domains may be of benefit to the most patients (17). There is also no indication that boosting one cognitive domain rather than another might improve community function (e.g., 18). Given these findings, we consider the key challenge at this stage of the field's development to be an understanding of which therapeutic techniques will provide the most benefit (9). While cognitive remediation therapies all involve massed practice on training tasks, there are key differences in how therapies attempt to bring about cognitive benefits. The greatest difference emerges between studies that have taken a strategy-based approach and a drill and practice approach. A previous meta-analysis (9) found that drill and practice had a greater effect on cognition than a strategy-based approach. However, the reverse was found for functioning.
To determine the most effective treatment approach for key outcomes, it is crucial to identify whether particular groups of patients benefit more (or less) from cognitive remediation therapies in order for scarce resources to be deployed to the greatest effect. There are a number of reasons why participant characteristics are likely to limit the treatment effect. First, age has been found to be a predictor of outcome in two studies (19, 20) and could be an important moderator variable given that some studies have recruited from markedly older populations (21) relative to others (22, 23). Baseline symptoms have been cited as a barrier to engagement in cognitive-behavioral therapy (CBT) for psychosis trials (24, 25). It is conceivable that cognitive remediation therapy could be similarly affected by patients who are distracted by symptoms or distressed.
The methodology of cognitive remediation studies has been regarded by both the National Institute for Clinical Excellence and the Patient Outcomes Research Team as a problematic factor in judging the effect size of studies (26, 27). A lack of rigor is known to affect the treatment effect estimates in both medication and psychological treatment trials of people with schizophrenia (28, 29). In particular, poorer quality masking of allocation to treatments is associated with up to a 40% increase in estimated treatment benefit in mental health studies as well as for studies in circulatory and digestive diseases and in obstetrics. A recent systematic review of CBT for psychosis showed the treatment effect inflation to be 50%–100% (29). To date, no meta-analysis of cognitive remediation has investigated methodological rigor. Since it is now on the brink of being incorporated into health services, such an analysis is essential not only to guide current service providers but also to help new research.
The present meta-analysis assesses treatment effects using double the number of studies included in the most recent analysis, and thus we could investigate more moderating effects of treatment and patient characteristics. However, our analysis is also novel in its investigation of the internal and external validity of the studies driving these treatment effects.
Method
Data Sources
Multiple systematic searches up to June 2009 were conducted using Embase, MEDLINE, Current Contents, Web of Science, PsycINFO, and the Cochrane Collaboration Controlled Trials Register. The following search terms were used as either key terms or keywords: (“cognitive” or “cognit*”) AND (“training” or “remediation” or “rehabilitation” or “enhancement”) AND “schizophrenia” AND (“random” or “randomized control trial” or “clinical trial”). The reference lists of articles fulfilling all criteria were hand-searched for other relevant studies. In addition, members of the Cognitive Remediation Experts Working Group who represent English-, French-, German-, Spanish-, and Italian-speaking countries were contacted regarding studies that did not appear in our literature searches.
Study Inclusion
All articles with an English abstract were included, producing 109 reports that were examined to identify the following criteria: 1) intervention fulfilling the standard Cognitive Remediation Experts Workshop definition for cognitive remediation; 2) a majority (≥70%) of participants with a diagnosis of schizophrenia; 3) all participants receiving standard care, including appropriate medication; 4) a comparison group and allocation procedure; and 5) a cognitive or functional outcome distinct from the trained tasks. These criteria excluded 46 reports (criterion 1, N=5; criterion 2, N=2; criterion 4, N=20; criterion 5, N=6; [13 reports provided inappropriate or insufficient data, which could not be resolved through contact with authors]), leaving 39 key reports of 40 independent studies among the remaining 63 reports.
Data Extraction
Trial details for deriving effect sizes as well as other variables were extracted by two authors of the present review (Drs. Huddy and Cellard). Uncertainty concerning a study was resolved through contact with the study authors. Few assumptions were made, with the exception that effect sizes were chosen when all treatment was concluded and follow-up effect sizes were calculated on the basis that there was a period with no treatment.
Measures
Trial quality
Trial quality was assessed using the Clinical Trials Assessment Measure (29, 30), a 15-item reliable and valid measure of trial methodology for psychological treatment studies. It assesses 1) sample characteristics (geographical cohort, referred sample, etc.); 2) allocation to treatment (randomization, blind allocation, etc.); 3) comparison treatments (e.g., a comparison group for nonspecific treatment effects); 4) outcome assessments (e.g., standardized outcomes, participants unaware of group allocation); 5) treatment description (e.g., a protocol, fidelity assessment); and 6) appropriate analysis (e.g., intention to treat). The maximum score is 100.
Two authors independently rated the studies with high reliability (intraclass coefficient=0.9). We sent all agreed-upon ratings to the study authors for approval. In cases where there was disagreement, supplementary evidence was requested. Only three study authors failed to reply. Following author feedback and evaluation of supplementary information, 57% of total Clinical Trial Assessment Measure scores changed by an average increase of 7.3 points.
Putative treatment moderators
Putative moderators were study vintage (years since publication date), therapy duration, computer presentation, presence of adjunctive psychiatric rehabilitation, and type of therapy (drill and practice versus drill plus strategy training as reviewed by McGurk et al. [9]). In drill and practice, the main focus is to engage cognitive processing by training on progressively more difficult exercises. Some researchers assume that this leads to more efficient neural responses and facilitates other aspects of cognition (e.g., 31). In drill and practice, there is no explicit input on how tasks might be more effectively completed. Adopting more efficient processes is determined by chance as participants try (or do not try) different approaches. In contrast, the drill plus strategy approach involves an explicit focus on teaching strategy use (e.g., initially identifying situations that trigger cognitive problems, such as memory lapses, then learning strategies, such as mnemonics, to aid remembering in therapy and then transferring these skills to everyday life). Studies were only categorized as drill plus strategy if they had some training procedures involving how to carry out tasks.
Putative patient characteristic moderators
There is evidence of potential effects of age (19, 20) and symptoms (24, 25). Data for age were taken from the mean ages in the studies. For symptoms, we converted baseline Positive and Negative Syndrome Scale and Brief Psychiatric Rating Scale scores (N=26) to Clinical Global Impression scores, using the Leucht et al. procedure (32).
Skewness
All continuous moderator variables were examined for skewness, and both study vintage and treatment duration were skewed. Treatment duration was corrected using square-root transformation. However, study vintage was affected by an outlier study (33) that was published 16 years before the next oldest study. When this outlier was removed, the study vintage variable was no longer skewed, and thus it was investigated without any transformation (except removal of the outlier).
Meta-Analytic Procedure
Effect size calculation
Effect sizes (Cohen's d) of cognitive skill, symptom, and functional differences were calculated using the following equation:
Effect size (d)=(Mt–Mc)/SDpooled
The Mc indicates the mean for the comparison group, and SDpooled indicates the pooled standard deviation for the two groups.
The estimate of the standard error of the effect size (Cohen's d) was calculated using the following formula:
SE(d)=sqrt([nt+nc]/[nt×nc])]+(d×2/[2×(nt+nc–2)])
The nt and nc denote the sample size for both the treatment and comparison groups (see Cooper and Hedges [34]).
The analysis default was to use the active comparison group whenever possible. If the group means were not available, analysis of variance F values that covaried baseline scores or t values were used to derive effect sizes using methods described by Thalheimer and Cook (35).
Primary outcomes
No therapy targets a sole cognitive domain, and cognitive outcomes reflect processing in several cognitive domains. We therefore designated the primary outcome as the global cognitive effect (averaged across all reported cognitive outcomes) that best represents the target for cognitive remediation therapy. This method has been used in most other meta-analyses (e.g., 7, 9, 36). All extracted measures of cognition, symptoms, and functioning are described in Table 1 of the data supplement accompanying the online version of this article. There were 99 cognitive outcomes at posttreatment refined into the Measurement and Treatment Research to Improve Cognition in Schizophrenia (37) group domains. Composite effect sizes were derived by averaging the available effect sizes of individual measures making up the composite.
Composites do not take into account covariation and constitute a conservative estimate, since the covariance would increase the composite effect size (38) so that it would always be greater than that of single measures. To establish whether composite measures were in the same range, we contrasted them with individual tests (Digit Span task, Wisconsin Card Sorting Test, Trail Making Test, and Continuous Performance Test) that were used in more than 10 studies.
Symptoms were reported at baseline in 29 studies and at outcome in 20 studies using eight measures. Functioning was reported in 19 studies using 16 measures (see Table 1 in the data supplement). Fourteen separate meta-analyses were carried out for posttreatment effects (global cognition, N=1; cognitive domains, N=7; individual cognitive measures, N=4; symptoms, N=1; and functioning, N=1). Three additional analyses were conducted for durability of global cognition, symptoms, and functioning.
Statistical procedures
Descriptive statistics and methodological quality were explored to investigate changes over time or specific biases. Meta-analyses used random-effects models and weighted effect sizes and were conducted with STATA software (StataCorp, College Station, Tex.) (39). The chi-square value of the homogeneity of effects was determined with the Q statistic (40). Study effect sizes were examined to identify whether any pretreatment cognitive differences biased the results or whether they were driven by outlier effects.
Mediator and moderator effects
When there was significant heterogeneity and at least 20 studies that provided data, metaregression analyses were carried out. The following individual moderators were considered: methodological rigor (Clinical Trial Assessment Measure variables [total score, masking, comparison group, and randomization]); participant characteristics (age, gender, proportion of participants with a confirmed diagnosis of schizophrenia, baseline symptom severity, impaired cognition as an inclusion criterion); and treatment characteristics (length, therapy type [drill and practice versus drill plus strategy], computer use, adjunctive rehabilitation). Treatment and patient moderator analyses were also conducted after covarying for methodological rigor.
Results
Corpus of Studies
Thirty-nine separate reports of 40 studies, with 2,104 participants, fulfilled all inclusion criteria. Summary characteristics of included studies are provided in Table 2 of the data supplement.
Sample characteristics
Study samples consisted of individuals in their mid-thirties (mean age=35.8 years [SD=7.1], range=15.3–48.3) who were mostly men (N=37, mean=67% [SD=14.2], range=30%–100%) with approximately 11.7 years of education (N=27, range=10.2–13.4). The proportion of inpatients and outpatients was balanced (47% versus 45%, respectively), with 7% of studies recruiting from both in- and outpatients. Symptom severity, when reported (N=26), was in the mild to moderate range. Within-study ranges suggested that some studies included more severely symptomatic individuals.
Study characteristics
Sample sizes were small (mean=53, range=10–145), with larger sample sizes appearing among the more recent studies ([N=40] Spearman's rho=0.42, p=0.007). Most studies were carried out in the United States (N=21), although 11 countries were represented. The average number of cognitive domains measured was 3.4, with a range of 1–6. Studies concentrating on only one domain appeared among the earliest studies and measured mainly speed of processing and attention/vigilance.
Treatment characteristics
Thirty-one studies used individual remediation and a total of nine group treatments. One-quarter of therapy involved the use of drill and practice exercises on a computer, without additional psychiatric rehabilitation. For computerized studies, it is not clear how much time was spent with a therapist, and author feedback indicates that this varied by participant. Fourteen different treatments were represented, with only three (21, 31, 41) not being replicated or independently replicated.
Only three studies (2, 31, 42) paid participants to undergo therapy, and in each of these payment was made to participants in both the experimental and comparison groups. In the Bell et al. (2) and Sartory et al. (42) studies, payment was made so that the experimental treatment group would not lose money, since payment was contingent upon taking part in vocational rehabilitation. Overall, the attrition rate was 11.0%, with a range of 0%–47.5%.
Twenty-one studies used drill and practice, and 19 used drill plus strategy. The average length of treatment was 32.2 hours (range=4–130), provided across 16.7 weeks (range=2–104). Therapy intensity was 2.2 sessions per week (range=0.6–5). Drill and practice treatments were shorter than drill plus strategy training (Mann-Whitney U test: hours: U=114, p=0.02; weeks: U=109, p=0.01), but the two approaches did not differ in intensity. Among studies using drill and practice, those that employed a computer-assisted program outnumbered those that did not (N=15 versus N=6, respectively), but the opposite was true for studies using drill plus strategy training (N=8 versus N=11). However, the difference was not statistically significant. Few programs utilized adjunctive psychiatric rehabilitation (27.5%), with no difference between drill and practice and drill plus strategy.
Trial Quality
Table 1 summarizes the trial methodology, year of publication, and breakdown of Clinical Trial Assessment Measure scores for all 40 studies examined. In this set of trials (N=39), the mean score was 57.4 (SD=12.3; range=35–87) out of a maximum of 100. Internal validity problems were sample size (60% were too small), lack of independent randomization (70%), lack of treatment fidelity assessment (80%), and group allocation masking (73%). The latter factor is known to inflate effect sizes.
| Effect Size | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Study and Year of Publication | Sample (maximum 10) | Allocation Procedure (maximum 16) | Assessment (maximum 32) | Comparison (maximum 16) | Analysis (maximum 15) | Treatment Description (maximum 11) | Clinical Trial Assessment Measure Total Score (maximum 100) | Cognition | Symptoms | Functioning |
| Meichenbaum and Cameron (study 2 [33]), 1973 | 2 | 10 | 16 | 10 | 15 | 6 | 59 | 0.93 | 1.89 | 3.50 |
| Meichenbaum and Cameron (study 1 [33]), 1973 | 2 | 10 | 6 | 16 | 15 | 6 | 55 | 2.35 | ||
| Benedict and Harris (46), 1989 | 2 | 10 | 3 | 16 | 15 | 6 | 52 | 1.57 | ||
| Olbrich and Mussgay (47), 1990 | 2 | 0 | 6 | 10 | 15 | 3 | 36 | 0.21 | 0.53 | |
| Hermanutz and Gestrich (48), 1991 | 2 | 10 | 16 | 16 | 15 | 6 | 65 | 0.46 | 0.26 | –0.47 |
| Benedict et al. (49), 1994 | 2 | 10 | 6 | 6 | 9 | 6 | 39 | 0.55 | ||
| Burda et al. (50), 1994 | 7 | 10 | 16 | 6 | 9 | 6 | 54 | 0.57 | ||
| Field et al. (51), 1997 | 2 | 10 | 6 | 10 | 10 | 6 | 44 | 0.85 | ||
| Medalia et al. (52), 1998 | 7 | 10 | 6 | 10 | 4 | 6 | 43 | 0.29 | 0.24 | |
| Spaulding et al. (53), 1999 | 7 | 10 | 32 | 10 | 9 | 11 | 79 | 0.22 | 0.14 | 0.53 |
| Wykes et al. (54, 55), 1999, 2003 | 5 | 16 | 16 | 10 | 15 | 6 | 68 | 0.20 | 0.61 | 0.06 |
| Medalia et al. (treatment 1) (56), 2000; Bark et al. (57), 2003a | 2 | 10 | 6 | 16 | 9 | 6 | 49 | –0.03 | 0.11 | |
| Bell et al. (2, 58–60), 2001–2007; Fiszdon et al. (61, 62), 2004, 2005a | 7 | 16 | 6 | 10 | 15 | 6 | 60 | 0.47 | 0.14 | |
| Hadas-Lidor et al. (63), 2001 | 7 | 10 | 16 | 10 | 5 | 6 | 54 | 1.87 | ||
| Medalia et al. (treatment 2) (64), 2001 | 2 | 10 | 6 | 16 | 4 | 6 | 44 | 0.58 | ||
| Bellucci et al. (65), 2002 | 2 | 10 | 26 | 6 | 15 | 6 | 65 | 0.46 | 0.74 | |
| van der Gaag et al. (66), 2002 | 2 | 0 | 6 | 10 | 15 | 6 | 39 | 0.12 | ||
| López-Luengo and Vázquez (67), 2003 | 2 | 10 | 6 | 6 | 5 | 6 | 35 | 0.45 | ||
| Hogarty et al. (68, 69), 2004, 2006 | 7 | 10 | 16 | 10 | 9 | 6 | 58 | 0.64 | 0.09 | 0.49 |
| Ueland and Rund (22, 70), 2004, 2005 | 2 | 10 | 6 | 10 | 15 | 6 | 49 | –0.18 | 0.15 | 0.38 |
| McGurk et al. (3, 4), 2007, 2005 | 2 | 16 | 26 | 6 | 11 | 6 | 67 | 0.44 | 0.46 | 1.09 |
| Sartory et al. (42), 2005 | 2 | 10 | 26 | 6 | 15 | 6 | 65 | 0.58 | ||
| Silverstein et al. (71), 2005 | 2 | 10 | 16 | 10 | 5 | 11 | 54 | –0.18 | –0.29 | 0.24 |
| Vauth et al. (72), 2005 | 7 | 10 | 16 | 16 | 11 | 3 | 63 | 0.90 | –0.35 | |
| Wölwer et al. (73), 2005 | 2 | 13 | 26 | 16 | 11 | 6 | 74 | –0.24 | ||
| Penades et al. (74), 2006 | 2 | 16 | 16 | 16 | 11 | 6 | 67 | 1.02 | –0.16 | 0.61 |
| Wykes et al. (23), 2007 | 10 | 16 | 6 | 6 | 11 | 11 | 60 | 0.13 | –0.20 | –0.03 |
| Wykes et al. (44), 2007 | 10 | 16 | 29 | 6 | 15 | 11 | 87 | 0.06 | 0.05 | 0.18 |
| Bell et al. (75), 2008; Greig et al. (76), 2007 | 7 | 16 | 6 | 10 | 15 | 6 | 60 | 0.31 | 0.30 | |
| Kurtz et al. (77), 2007 | 2 | 10 | 29 | 10 | 9 | 6 | 66 | 0.36 | ||
| Hodge et al. (78), 2010 | 2 | 13 | 16 | 6 | 5 | 11 | 53 | 0.29 | ||
| Twamley et al. (79), 2008 | 2 | 10 | 26 | 6 | 0 | 6 | 50 | 0.34 | 0.45 | 0.32 |
| Lindenmayer et al. (82), 2008 | 7 | 16 | 6 | 10 | 15 | 3 | 57 | 0.24 | ||
| Cavallaro et al. (80), 2009 | 7 | 13 | 6 | 10 | 9 | 6 | 51 | 0.23 | 0.39 | |
| Kern et al. (81), 2009 | 2 | 10 | 29 | 10 | 5 | 11 | 67 | 0.99 | ||
| Silverstein et al. (83), 2009 | 7 | 10 | 13 | 10 | 5 | 11 | 56 | 0.19 | ||
| Fisher et al. (31, 84), 2009, 2010 | 7 | 13 | 26 | 10 | 9 | 6 | 71 | 0.99 | ||
| Lecardeur et al. (41), 2009 | 2 | 0 | 6 | 16 | 15 | 3 | 42 | 0.01 | 0.25 | |
| Dickinson et al. (21), 2010 | 7 | 16 | 29 | 10 | 9 | 11 | 82 | 0.06 | 0.06 | –0.13 |
| Eack et al. (85), 2009 | 7 | 16 | 6 | 10 | 11 | 6 | 56 | 0.60 | 0.73 | 1.36 |
| Range | 2–10 | 0–16 | 3–32 | 6–16 | 0–15 | 3–11 | 35–87 | |||
a
Data indicate analyses using the Clinical Trial Assessment Measure (23, 30). The mean (standard deviation) values for the sample size, allocation procedure, assessment, comparison, analysis, treatment description, and Clinical Trial Assessment Measure total score are as follows: 4.2 (SD=2.7), 11.05 (SD=4.1), 14.5 (SD=9.2), 10.4 (SD=3.5), 10.5 (SD=4.2), 6.7 (SD=2.4), and 57.4 (SD=12.3), respectively.
Methodological quality improved over time, with some significant improvements, for example, for the method of group allocation ([N=39] Spearman's rho=0.40, p=0.01). However, some quality ratings diminished, for example, for analyses that included all participants randomly assigned ([N=40] Spearman's rho=–0.33, p=0.04). The dropout rate was higher than 15% in 12 studies, which is above the minimum level that would cause many statisticians to question the validity of the study findings.
There were no relationships between trial quality and type of remediation approach or whether or not the approach was computer assisted.
Meta-Analysis Results
Effects of cognitive remediation therapy on cognitive skills posttreatment
Two studies reported only functioning, and thus 38 studies provided measures to the global cognition effect size. Figure 1 illustrates a forest plot for global cognition, depicting an overall positive effect of cognitive rehabilitation of 0.45 (95% confidence interval [CI]=0.31–0.59). The statistical data for all cognitive and functioning outcomes at posttreatment as well as cognitive outcomes at follow-up assessment are presented in Table 2.
FIGURE 1. Forest Plot of Global Cognition Among Studies in Cognitive Remediation Therapya
a Studies are listed by their Clinical Trial Assessment Measure scores (Table 1) in ascending order.
| Heterogeneity Test | |||||||
|---|---|---|---|---|---|---|---|
| Variable | Mean | 95% Confidence Interval | Q Statistic | df | p | Number of Studies | Total Sample Size |
| Global cognition | 0.448* | 0.306 to 0.590 | 76.18 | 37 | 0.00 | 38 | 1,982 |
| Cognitive domains | |||||||
| Attention/vigilance | 0.250* | 0.080 to 0.419 | 19.47 | 15 | 0.19 | 16 | 901 |
| Speed of processing | 0.258* | 0.072 to 0.445 | 52.64 | 23 | 0.000 | 24 | 1,332 |
| Verbal working memory | 0.346* | 0.186 to 0.506 | 25.69 | 19 | 0.14 | 20 | 1,029 |
| Verbal learning and memory | 0.410* | 0.273 to 0.548 | 29.24 | 22 | 0.14 | 23 | 1,346 |
| Visual learning and memory | 0.150 | –0.077 to 0.377 | 13.37 | 9 | 0.05 | 10 | 547 |
| Reasoning/problem solving | 0.572* | 0.222 to 0.922 | 203.25 | 24 | 0.00 | 25 | 1,389 |
| Social cognition | 0.651* | 0.331 to 0.972 | 15.41 | 6 | 0.03 | 7 | 539 |
| Specific cognitive tests | |||||||
| Digit Span | 0.422* | 0.226 to 0.617 | 16.54 | 13 | 0.17 | 13 | 713 |
| Trail Making Test | 0.319* | 0.077 to 0.560 | 21.39 | 12 | 0.03 | 13 | 664 |
| Wisconsin Card Sorting Test | 0.335* | 0.188 to 0.481 | 10.26 | 12 | 0.59 | 13 | 830 |
| Continuous Performance Test | 0.206 | –0.009 to 0.422 | 13.14 | 9 | 0.16 | 10 | 581 |
| Other outcomes | |||||||
| Symptoms | 0.177* | 0.034 to 0.321 | 23.50 | 19 | 0.22 | 20 | 1,114 |
| Functioning | 0.418* | 0.216 to 0.620 | 39.35 | 18 | 0.003 | 19 | 1,036 |
| Follow-up assessment | |||||||
| Global cognition | 0.428* | 0.184 to 0.671 | 17.27 | 10 | 0.07 | 11 | 731 |
| Symptoms | 0.174 | –0.031 to 0.481 | 11.12 | 7 | 0.134 | 8 | 527 |
| Function | 0.372* | 0.110 to 0.635 | 25.72 | 11 | 0.005 | 12 | 745 |
a
a The Dickinson et al. (21) study was excluded from analyses of attention/vigilance and verbal learning because composites included incompatible component tests (e.g., visual and verbal learning).
*p<0.05.
Eleven studies had pretreatment differences >0.2, with seven already showing better cognition in the allocated treatment group as well as a large global cognition effect size (0.7, 95% CI=0.1–1.2). However, even when these studies are excluded, there is still a significant effect size ([N=27] 0.4, 95% CI=0.28–0.54).
With only two exceptions, visual learning and memory and Continuous Performance Test ratings, all cognitive domains demonstrated significant effect sizes from 0.25 to 0.65. Domain effect sizes are affected by the set of studies that contributes to them, and thus no further inferences can be drawn about differences between them.
Individual test effects completely overlapped the composite effect sizes, suggesting that our conservative method of combining measures did not enhance their effects. Heterogeneity was found in global cognition as well as in speed of processing, verbal learning and memory, reasoning and problem solving, and Trail Making Test ratings. However, only 13 studies contributed to the Trail Making Test, and thus no further analyses were carried out on this measure.
A sensitivity analysis that excluded each study once made little difference to the global cognition effect size estimate (range=0.43–0.45). The same was found for an analysis that excluded three outliers (effect size=0.37 [SD>1.5], 95% CI=0.28–0.47).
Durability
The effects of treatment on global cognition were durable ([N=11] effect size=0.43, 95% CI=0.18–0.67).
Therapy effects on symptoms and functioning
There was a significant small-to-medium effect on functioning outcomes at both posttreatment and follow-up assessment. There was also a small, significant effect of cognitive remediation on symptoms at posttreatment, but it was no longer significant at follow-up assessment.
Publication Bias
Funnel plots (see Figure 1 in the data supplement) provided no evidence of publication bias producing a “file draw problem.” Statistical tests using Begg's method confirmed this for global cognition (z=0.99, p=0.32), symptoms (z=1.10, p=0.27), and functioning (z=0.26, p=0.80). The relationship between study vintage and global cognition was examined using metaregression, and no significant relationship was found.
Factors Affecting Treatment Benefit
Domains with significant heterogeneity and 20 contributing effect sizes are included in Table 3. Domains with fewer than 20 effect sizes (i.e., functioning) were explored using categorical analysis where possible.
| Analysis | |||||
|---|---|---|---|---|---|
| Characteristic | N | Metaregression Coefficient | 95% Confidence Interval | t | p |
| Methodology | |||||
| Clinical Trial Assessment Measure scoreb | |||||
| Global cognition | 38 | –0.004 | –0.02 to 0.01 | –0.67 | 0.51 |
| Speed of processing | 24 | –0.004 | –0.02 to 0.15 | –0.44 | 0.66 |
| Reasoning and problem solving | 25 | –0.010 | –0.04 to 0.02 | –0.68 | 0.50 |
| Masking | |||||
| Global cognition | 38 | –0.018 | –0.05 to 0.02 | –1.08 | 0.29 |
| Speed of processing | 24 | –0.012 | –0.06 to 0.03 | –0.56 | 0.58 |
| Reasoning and problem solving | 25 | –0.054 | –0.13 to 0.02 | –1.49 | 0.15 |
| Control type (active/passive) | |||||
| Global cognition | 43 | 0.174 | –0.13 to 0.48 | 1.15 | 0.26 |
| Speed of processing | 24 | –0.163 | –0.72 to 0.39 | –0.61 | 0.55 |
| Reasoning and problem solving | 25 | 0.217 | –0.65 to 1.10 | 0.52 | 0.61 |
| Independent randomization | |||||
| Global cognition | 38 | –0.031 | –0.14 to 0.08 | –0.59 | 0.56 |
| Speed of processing | 24 | –0.048 | –0.20 to 0.10 | –0.068 | 0.50 |
| Reasoning and problem solving | 25 | –0.096 | –0.34 to 0.15 | –0.80 | 0.43 |
| Participantc | |||||
| Age | |||||
| Global cognition | 38 | 0.002 | –0.02 to 0.03 | 0.20 | 0.85 |
| Speed of processing | 24 | 0.017 | –0.01 to 0.05 | 1.17 | 0.25 |
| Reasoning and problem solving | 25 | 0.007 | –0.04 to 0.06 | 0.28 | 0.78 |
| Gender | |||||
| Global cognition | 35 | –0.004 | –0.02 to 0.01 | –0.62 | 0.54 |
| Speed of processing | 22 | 0.002 | –0.02 to 0.02 | 0.022 | 0.83 |
| Reasoning and problem solving | 24 | 0.007 | –0.04 to 0.03 | –0.45 | 0.66 |
| Impaired cognition as inclusion criterion | |||||
| Global cognition | 38 | 0.204 | –0.11 to 0.52 | 1.30 | 0.20 |
| Speed of processing | 24 | 0.018 | –0.47 to 0.51 | 0.08 | 0.94 |
| Reasoning and problem solving | 25 | 0.281 | –0.54 to 1.10 | 0.71 | 0.49 |
| Baseline symptoms | |||||
| Global cognition | 25 | –0.145 | –0.31 to 0.02 | –1.82 | 0.08 |
| Speed of processing | |||||
| Reasoning and problem solving | |||||
| Therapyc | |||||
| Length (hours) | |||||
| Global cognition | 38 | 0.036 | –0.022 to 0.95 | 1.25 | 0.22 |
| Speed of processing | 24 | 0.01 | –0.12 to 0.10 | –0.31 | 0.76 |
| Reasoning and problem solving | 25 | 0.108 | –0.030 to 0.247 | 1.62 | 0.12 |
| Drill/drill strategy | |||||
| Global cognition | 38 | –0.022 | –0.33 to 0.29 | –0.15 | 0.89 |
| Speed of processing | 24 | –0.257 | –0.68 to 0.17 | –1.26 | 0.22 |
| Reasoning and problem solving | 25 | –0.451 | –0.29 to 1.19 | 1.26 | 0.22 |
| Computerized (yes/no) | |||||
| Global cognition | 38 | –0.041 | –0.37 to 0.29 | –0.25 | 0.80 |
| Speed of processing | 24 | –0.258 | –0.72 to 0.21 | –1.15 | 0.26 |
| Reasoning and problem solving | 25 | 0.334 | –0.40 to 1.1 | 0.94 | 0.36 |
| Adjunctive psychiatric rehabilitation | |||||
| Global cognition | 41 | 0.105 | –0.22 to 0.43 | 0.66 | 0.51 |
| Speed of processing | 24 | –0.080 | –0.52 to 0.36 | –0.38 | 0.71 |
| Reasoning and problem solving | 25 | 0.140 | –0.65 to 0.93 | 0.37 | 0.72 |
a
Data indicate analyses containing significant heterogeneity and >20 effect sizes.
b
Analysis utilized the Clinical Trial Assessment Measure total score minus Q2, which refers to the sample size.
c
Analyses that were repeated using the Clinical Trial Assessment Measure and also included in the metaregression found the same results.
Methodological quality
Overall trial quality (total Clinical Trial Assessment Measure score) had no effect on most cognitive outcomes. There was also no effect on functioning outcome (poor method [Clinical Trial Assessment Measure score <65]: effect size=0.44, 95% CI=0.19–0.69 versus good method [score ≥65]: effect size=0.39, 95% CI=0.02–0.75).
Masking group allocation had no effect on cognitive (Table 3) or functioning outcomes (unmasked: effect size=0.41, 95% CI=0.15–0.67 versus masked: effect size=0.43, 95% CI=0.08–0.79).
Three studies that failed to meet our stringent criteria for random allocation were excluded from the analysis, but the cognitive effect size was not affected ([N=35] effect size=0.47, 95% CI=0.32–0.62). There was no effect of independent randomization on cognition or functioning (nonindependent allocation: effect size=0.41, 95% CI=0.18–0.64 versus independent allocation: effect size=0.42, 95% CI=0.05–0.80). However, eight studies with participants who had better pretreatment cognition had larger effects, and of these only one used independent allocation of participants (14%), while the rate of independent allocation was 38% in the wider corpus.
There was a significant effect of cognitive rehabilitation on global cognitive outcome irrespective of the type of control, suggesting a specific effect of cognitive remediation on a comparable treatment. For functioning, trials that used an active comparison group produced a significant effect, which was not present in trials that applied a passive comparison group, although these were few in number (active comparison [N=14]: effect size=0.47, 95% CI=0.24–0.71 versus passive comparison [N=3]: effect size=0.16, 95% CI=–0.16 to 0.492) and the difference was not significant.
Participant characteristics
There was no indication of an effect of age. Lower baseline symptoms were related to larger global cognitive effects at posttreatment. However, the effect of treatment continued to be significant. Consequently, symptoms did not prevent improvements in cognition, but at high levels the effect size was modest.
Cognitive impairment as an entry criterion did not affect cognition outcomes. For functioning, studies using impairment as an inclusion criterion showed a larger effect size than those studies that did not (effect size=0.37, 95% CI=0.05–0.70 versus effect size=0.48, 95% CI=0.17–0.79, respectively), although with no significant statistical difference.
Clinical factors
Although 38 studies reported medication status, only 13 reported more detailed data regarding dosage. A median split on chlorpromazine equivalence into high (791 mg/day [N=6]) and low (375 mg/day [N=6]) doses demonstrated equivalent global cognition effect sizes in high (0.48) and low groups (0.55). There was no significant difference between these two groups of studies.
Larger effect sizes were found in studies that included only participants with schizophrenia or schizoaffective disorder (0.5) compared with those that also included participants with other diagnoses (0.2), and these groups tended to be statistically different (Qb=2.7, p=0.1).
Therapy characteristics
There were no significant effects of remediation approach (drill and practice versus drill plus strategy), therapy duration, or computer use on cognitive outcomes.
Further exploratory analyses, as reviewed by McGurk et al. (9), on the effect of remediation programs on psychosocial functioning indicated significantly stronger effects (Qb=5.51, p=0.02) in studies that provided adjunctive psychiatric rehabilitation to all patients (effect size=0.59, 95% CI=0.30–0.88) compared with studies that examined cognitive remediation alone (effect size=0.28, 95% CI=–0.02 to 0.58). In addition, there was a significant treatment effect for remediation only when a strategic approach was used (drill and practice: effect size=0.34, 95% CI=–0.11 to 0.78; drill plus strategy: effect size=0.47, 95% CI=0.22–0.73), although the difference was not significant. When only studies that provided additional psychiatric rehabilitation (N=8) were included, those using drill plus strategy programs (N=8) produced significantly larger effects ([N=4] effect size=0.8, 95% CI=0.4–1.2; Qb=6.6, p=0.01) compared with those using drill and practice programs ([N=4] effect size=0.3, 95% CI=0.05–0.6).
None of the results changed when overall methodology was controlled in the metaregression analyses of moderators.
Discussion
The present meta-analysis on cognitive remediation therapy is the most comprehensive to date, containing 2,104 participants in 39 reports on 40 independent studies. In comparison, the most recent reviews conducted by the National Institute for Clinical Excellence (27) (17 studies, 1,084 participants), Patient Outcomes Research Team (26) (33 studies), and McGurk et al. (9) (26 studies, 1,151 participants) contained far fewer studies, treatments, and participants.
Is Cognitive Rehabilitation Effective?
This meta-analysis demonstrates a small to moderate effect of cognitive rehabilitation on cognitive outcomes at posttreatment and follow-up assessment in individuals with a diagnosis of schizophrenia. This result provides a fair representation of the published data, and there is little evidence of bias produced by trial methodology. There is also no evidence of publication bias, which was unlikely because current clinical equipoise about the usefulness of cognitive rehabilitation means that studies are publishable irrespective of whether they are successful. Older studies did not show the usual statistical trajectory toward higher effect sizes. In terms of external validity, most studies include relatively stable patients with a diagnosis of schizophrenia, both inpatients and outpatients. This is the identified group of patients considered to be in need of additional intensive treatment to improve recovery trajectory.
Our results replicate other reviews and meta-analyses (7–10, 12, 13) and further suggest that irrespective of therapy characteristics, cognitive rehabilitation can provide benefits to patients with cognitive difficulties. This is in contrast to two recent guidance reviews (26, 27), neither of which suggested that cognitive remediation should be adopted. The discrepancy with the United Kingdom National Institute for Clinical Excellence (27) is explained by their entry criteria, which excluded large-scale methodologically sound studies that included work rehabilitation within treatment as usual.
Is the Effect of Cognitive Remediation Therapy Dependent on Trial Methodology?
Bias in both the choice of populations and study method can affect the study results and may lead to the unsafe conclusion that a treatment is effective when it is not. Cognitive remediation trials were similar in rigor to studies of other psychological therapies (e.g., average Clinical Trial Assessment Measure scores for CBT for psychosis [29] and cognitive remediation). However, although trial methodology has serious consequences concerning CBT for psychosis trial estimates of effectiveness, particularly masked assessment, it had no effect on cognitive outcomes from cognitive remediation studies. This result should not be surprising, since the outcomes for CBT for psychosis are open to rater bias because they are based on patient interviews for symptom scores. However, cognitive test outcomes are specifically designed to exclude the effects of rater bias.
Clinical Implications
Do participants' characteristics make a difference? Although having more symptoms is associated with smaller effects, these participants still benefit from cognitive rehabilitation. Our medication data did not indicate that this was a bar to improvement through cognitive remediation, neither did the use of cognitive impairment as an inclusion criterion. We therefore conclude that it should be offered to all.
There was no evidence that age was a key moderator variable despite individual study evidence (19, 20). However, there was a narrow age range, with 25 studies (62.5%) reporting a mean age between 30 and 40 years. Our recommendations are therefore not as strong until other age groups have been tested.
Which cognitive remediation treatment works best? The present corpus of studies varies in terms of the way in which rehabilitation is provided. Most treatments were independently replicated, and many have multiple replications. We did not discover any variables to account for the heterogeneity in cognitive effects. Better differentiation can be made for treatment to improve functioning. The results of this meta-analysis suggest that functioning outcomes are best achieved by adding cognitive remediation to other rehabilitation programs, which boosts their effects. When other rehabilitation is included, strategic approaches rather than drill and practice achieve better outcomes, probably because they support transfer of training. These two factors may provide the most potent form of therapy for improving functional outcome.
Variations in treatment presentation have been commented on by several reviewers (26, 27). Our interpretation is that there are approximately 14 different treatments that have few salient differences; rather, they lie along dimensions of learning support as well as support for transfer to community functioning. All cognitive remediation therapies address a broad range of cognitive skills, even if they also include specific outcomes such as social cognition. This is shown in the cognitive outcomes tested within a study. What is more important than the surface characteristics (e.g., using a computer) is the technique of specific and explicit training of strategies and the use of various transfer techniques, as shown in the improved functioning outcomes for these approaches.
Research Implications
Given the evidence across a number of studies of the efficacy of cognitive rehabilitation, research must try to establish what variation in participants, as well as in treatments, will provide the most benefit for the most people. Those studies that do not produce significant effects have high information value because they allow us to consider variables that are important to both the personalization agenda and study design.
A number of these negative studies have appeared in the literature but have not always been well controlled or well explicated. This is not the case with a recent study conducted by Dickinson et al. (21), which has excellent methodology, with a total Clinical Trial Assessment Measure score of 82 out of 100, but produced a small nonsignificant effect size (0.06). This study has the second oldest group of participants (mean age=48 years [SD=7.65]) among the studies in our meta-analysis. Although age was not a predictor in our meta-analysis, there are data at a study level showing that older participants have poorer treatment response (e.g., 19, 20). Those investigators with study data from across the age span might carry out secondary analyses to identify whether age is a moderator. If age is found to be a moderator, then this would mean adaptations of treatment for older participants to increase effectiveness.
The Dickinson et al. study was designed to identify specific treatment effects and thus had an active comparison group that shared several elements in common with the experimental treatment group. This is an excellent way of identifying ingredients that are crucial to outcome, but this design does not allow us to detect whether the experimental therapy was beneficial. In the future, we recommend that cognitive rehabilitation studies include both active and passive comparison groups, since this allows for not only a decision on essential treatment elements but also an assessment of whether the specific therapy demonstrates a significant effect and is therefore worth the investment of scarce healthcare resources.
Even though we have not discovered the essential elements of successful treatment, researchers need to begin to identify key issues for therapy implementation, such as acceptability. One measure is the dropout rate from treatment. The Dickinson et al. study had a 2.5-times greater dropout rate in the comparison arm than the experimental therapy arm, which suggests that the therapy was at least engaging. One independent consumer-led acceptability study (43) showed that cognitive remediation therapy (44) was acceptable and valued. It also showed that if participants did not perceive improvement in therapy, then they “felt worse,” and this finding was demonstrated in secondary analyses. Individuals whose memory improved were more likely to improve their self-esteem, whereas those with no memory improvement experienced a decrement. These studies and detailed analyses allow an informed evaluation of therapy acceptability as well as of identifying side effects. Both these features would influence which therapy to adopt. In addition, since health services are unlikely to be able to pay patients to take part in therapy, those treatment programs that pay patients for attendance (31) would need to stop in order to allow a balanced view of engagement.
Conclusions
It is safe to conclude that there is a small to moderate durable effect of cognitive remediation on cognition and functioning that is not affected by study methodology. If the target is to improve functioning, then adjunctive therapy is essential, with the best effects being shown when a more strategic cognitive remediation approach is adopted.
Acknowledgments
The authors thank the authors of the trials in the corpus of data.
Footnotes
Received June 16, 2010; revision received Oct. 13, 2010; accepted Nov. 8, 2010.
Drs. Wykes and McGurk have conducted trials of cognitive remediation therapy.
Supplementary Material
File (ajp_168_05_472_01.pdf)
- View/Download
- 111.71 KB
References
1.
Wykes T: Predicting symptomatic and behavioural outcomes of community care. Br J Psychiatry 1994; 165:486–492
2.
Bell M, Bryson G, Greig T, Corcoran C, Wexler BE: Neurocognitive enhancement therapy with work therapy: effects on neuropsychological test performance. Arch Gen Psychiatry 2001; 58:763–768
3.
McGurk SR, Mueser KT, Feldman K, Wolfe R, Pascaris A: Cognitive training for supported employment: 2–3 year outcomes of a randomized controlled trial. Am J Psychiatry 2007; 164:437–441
4.
McGurk SR, Mueser KT, Pascaris A: Cognitive training and supported employment for persons with severe mental illness: one-year results from a randomized controlled trial. Schizophr Bull 2005; 31:898–909
5.
Wykes T, Dunn G: Cognitive deficit and the prediction of rehabilitation success in a chronic psychiatric group. Psychol Med 1992; 22:389–398
6.
Wykes T, Katz R, Sturt E, Hemsley D: Abnormalities of response processing in a chronic psychiatric group: a possible predictor of failure in rehabilitation programmes? Br J Psychiatry 1992; 160:244–252
7.
Krabbendam L, Aleman A: Cognitive rehabilitation in schizophrenia: a quantitative analysis of controlled studies. Psychopharmacology (Berl) 2003; 169:376–382
8.
Kurtz MM, Moberg PJ, Gur RC, Gur RE: Approaches to cognitive remediation of neuropsychological deficits in schizophrenia: a review and meta-analysis. Neuropsychol Rev 2001; 11:197–210
9.
McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT: A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry 2007; 164:1791–1802
10.
Pilling S, Bebbington P, Kuipers E, Garety P, Geddes J, Martindale B, Orbach G, Morgan C: Psychological treatments in schizophrenia, II: meta-analyses of randomized controlled trials of social skills training and cognitive remediation. Psychol Med 2002; 32:783–791
11.
Twamley EW, Jeste DV, Bellack AS: A review of cognitive training in schizophrenia. Schizophr Bull 2003; 29:359–382
12.
Grynszpan OP, Perbal S, Pelissolo A, Fossati P, Jouvent R, Dubal S, Perez-Diaz F: Efficacy and specificity of computer-assisted cognitive remediation in schizophrenia: a meta-analytical study. Psychol Med 2011; 41:163–173
13.
Hayes RL, McGrath JJ: Cognitive rehabilitation for people with schizophrenia and related conditions. Cochrane Database Syst Rev 2000; 3:CD000968
14.
Wykes T, van der Gaag M: Is it time to develop a new cognitive therapy for psychosis: cognitive remediation therapy (CRT)? Clin Psychol Rev 2001; 21:1227–1256
15.
Bellack AS: Cognitive rehabilitation for schizophrenia: is it possible? is it necessary? Schizophr Bull 1992; 18:43–50
16.
Joyce EM, Roiser JP: Cognitive heterogeneity in schizophrenia. Curr Opin Psychiatry 2007; 20:268–272
17.
Wykes T, Huddy V: Cognitive remediation for schizophrenia: it is even more complicated. Curr Opin Psychiatry 2009; 22:161–167
18.
Reeder C, Newton E, Frangou S, Wykes T: Which executive skills should we target to affect social functioning and symptom change? a study of a cognitive remediation therapy program. Schizophr Bull 2004; 30:87–100
19.
McGurk SR, Mueser K: Response to cognitive rehabilitation in older versus younger persons with severe mental illness. Am J Psychiatr Rehab 2008; 11:90–105
20.
Wykes T, Reeder C, Landau S, Matthiasson P, Haworth E, Hutchinson C: Does age matter? effects of cognitive rehabilitation across the age span. Schizophr Res 2009; 113:252–258
21.
Dickinson D, Tenhula W, Morris S, Brown C, Peer J, Spencer K, Li L, Gold JM, Bellack AS: A randomized, controlled trial of computer-assisted cognitive remediation for schizophrenia. Am J Psychiatry 2010; 167:170–180
22.
Ueland T, Rund BR: A controlled randomized treatment study: the effects of a cognitive remediation program on adolescents with early onset psychosis. Acta Psychiatr Scand 2004; 109:70–74
23.
Wykes T, Newton E, Landau S, Rice C, Thompson N, Frangou S: Cognitive remediation therapy (CRT) for young early onset patients with schizophrenia: an exploratory randomized controlled trial. Schizophr Res 2007; 94:221–230
24.
Garety PA, Fowler DG, Freeman D, Bebbington P, Dunn G, Kuipers E: Cognitive-behavioural therapy and family intervention for relapse prevention and symptom reduction in psychosis: randomised controlled trial. Br J Psychiatry 2008; 192:412–423
25.
Tarrier N, Lewis S, Haddock G, Bentall R, Drake R, Kinderman P, Kingdon D, Siddle R, Everitt J, Leadley K, Benn A, Grazebrook K, Haley C, Akhtar S, Davies L, Palmer S, Dunn G: Cognitive-behavioural therapy in first-episode and early schizophrenia: 18-month follow-up of a randomised controlled trial. Br J Psychiatry 2004; 184:231–239
26.
Dixon LB, Dickerson F, Bellack AS, Bennett M, Dickinson D, Goldberg RW, Lehman A, Tenhula WN, Calmes C, Pasillas RM, Peer J, Kreyenbuhl J: The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull 2009; 36:48–70
27.
National Collaborating Centre for Mental Health: Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. London, National Institute for Health and Clinical Excellence, 2009
28.
Thornley B, Adams C: Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ 1998; 317:1181–1184
29.
Wykes T, Steel C, Everitt B, Tarrier N: Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull 2008; 34:523–537
30.
Tarrier N, Wykes T: Is there evidence that cognitive behaviour therapy is an effective treatment for schizophrenia? a cautious or cautionary tale? Behav Res Ther 2004; 42:1377–1401
31.
Fisher M, Holland C, Merzenich MM, Vinogradov S: Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia. Am J Psychiatry 2009; 166:805–811
32.
Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR: What does the PANSS mean? Schizophr Res 2005; 79:231–238
33.
Meichenbaum D, Cameron R: Training schizophrenics to talk to themselves: a means of developing attentional controls. Behav Therapy 1973; 4:515–534
34.
Cooper HM, Hedges LV: The Handbook of Research Synthesis. New York, Russell Sage Foundation, 1994
35.
Thalheimer W, Cook S: How to Calculate Effect Sizes From Published Research Articles: A Simplified Methodology. http://www.docstoc.com/docs/47860289/How-to-calculate-effect-sizes-from-published-research-A-simplified-methodology
36.
Ventura J, Hellemann GS, Thames AD, Koellner V, Nuechterlein KH: Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. Schizophr Res 2009; 113:189–199
37.
Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR: The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry 2008; 165:203–213
38.
Gleser LJ, Olkin I: Stochastically dependent effect sizes, in The Handbook of Research Synthesis. Edited by, Cooper HM, Hedges LV. New York, Sage Publications, 1994, pp 339–355
39.
StataCorp: Stata Statistical Software, Release 10. College Station, Tex. StataCorp, 2007
40.
Hedge LV, Olkin I: Statistical Methods for Meta-Analysis. New York, Academic Press, 1985
41.
Lecardeur L, Stip E, Giguere M, Blouin G, Rodriguez JP, Champagne-Lavau M: Effects of cognitive remediation therapies on psychotic symptoms and cognitive complaints in patients with schizophrenia and related disorders: a randomized study. Schizophr Res 2009; 111:153–158
42.
Sartory G, Zorn C, Groetzinger G, Windgassen K: Computerized cognitive remediation improves verbal learning and processing speed in schizophrenia. Schizophr Res 2005; 75:219–223
43.
Rose D, Farrier D, Doran A-M, Sporle T, Bogner D, Wykes T: What do clients think of cognitive remediation therapy: a consumer led investigation of satisfaction and side effects. Am J Psychiatr Rehab 2008; 11:181–204
44.
Wykes T, Reeder C, Landau S, Everitt B, Knapp M, Patel A, Romeo R: Cognitive remediation therapy in schizophrenia: randomised controlled trial. Br J Psychiatry 2007; 190:421–427
45.
Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, Fenton WS, Frese F, Goldberg TE, Heaton RK, Keefe RSE, Kern RS, Kraemer H, Stover E, Weinberger DR, Zalcman S, Marder SR: Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 2004; 56:301–307
46.
Benedict RH, Harris AE: Remediation of attention deficits in chronic schizophrenic patients: a preliminary study. Br J Clin Psychol 1989; 28(pt 2):187–188
47.
Olbrich R, Mussgay L: Reduction of schizophrenic deficits by cognitive training: an evaluative study. Eur Arch Psychiatry Clin Neurosci 1990; 239:366–369
48.
Hermanutz M, Gestrich J: Computer-assisted attention training in schizophrenics: a comparative study. Eur Arch Psychiatry Clin Neurosci 1991; 240:282–287
49.
Benedict RH, Harris AE, Markow T, McCormick JA, Nuechterlein KH, Asarnow RF: Effects of attention training on information processing in schizophrenia. Schizophr Bull 1994; 20:537–546
50.
Burda PC, Starkey TW, Dominguez F, Vera V: Computer-assisted cognitive rehabilitation of chronic psychiatric inpatients. Comput Hum Behav 1994; 10:359–368
51.
Field CD, Galletly C, Anderson D, Walker P: Computer-aided cognitive rehabilitation-possible application to the attentional deficit of schizophrenia: a report of negative results. Percept Mot Skills 1997; 85(pt 1):995–1002
52.
Medalia A, Aluma M, Tryon W, Merriam AE: Effectiveness of attention training in schizophrenia. Schizophr Bull 1998; 24:147–152
53.
Spaulding WD, Reed D, Sullivan M, Richardson C, Weiler M: Effects of cognitive treatment in psychiatric rehabilitation. Schizophr Bull 1999; 25:657–676
54.
Wykes T, Reeder C, Corner J, Williams C, Everitt B: The effects of neurocognitive remediation on executive processing in patients with schizophrenia. Schizophr Bull 1999; 25:291–307
55.
Wykes T, Reeder C, Williams C, Corner J, Rice C, Everitt B: Are the effects of cognitive remediation therapy (CRT) durable? results from an exploratory trial in schizophrenia. Schizophr Res 2003; 61:163–174
56.
Medalia A, Revheim N, Casey M: Remediation of memory disorders in schizophrenia. Psychol Med 2000; 30:1451–1459
57.
Bark N, Revheim N, Huq F, Khalderov V, Ganz ZW, Medalia A: The impact of cognitive remediation on psychiatric symptoms of schizophrenia. Schizophr Res 2003; 63:229–235
58.
Bell M, Bryson G, Wexler B: Cognitive remediation of working memory deficits: durability of training effects in severely impaired and less severely impaired schizophrenia. Acta Psychiatr Scand 2003; 108:101–109
59.
Bell M, Fiszdon J, Greig T, Wexler B, Bryson G: Neurocognitive enhancement therapy with work therapy in schizophrenia: 6-month follow-up of neuropsychological performance. J Rehabil Res Dev 2007; 44:761–770
60.
Bell MD, Bryson GJ, Greig TC, Fiszdon JM, Wexler BE: Neurocognitive enhancement therapy with work therapy: productivity outcomes at 6- and 12-month follow-ups. J Rehabil Res Dev 2005; 42:829–838
61.
Fiszdon JM, Bryson GJ, Wexler BE, Bell MD: Durability of cognitive remediation training in schizophrenia: performance on two memory tasks at 6-month and 12-month follow-up. Psychiatry Res 2004; 125:1–7
62.
Fiszdon JM, Whelahan H, Bryson GJ, Wexler BE, Bell MD: Cognitive training of verbal memory using a dichotic listening paradigm: impact on symptoms and cognition. Acta Psychiatr Scand 2005; 112:187–193
63.
Hadas-Lidor N, Katz N, Tyano S, Weizman A: Effectiveness of dynamic cognitive intervention in rehabilitation of clients with schizophrenia. Clin Rehabil 2001; 15:349–359
64.
Medalia A, Revheim N, Casey M: The remediation of problem-solving skills in schizophrenia. Schizophr Bull 2001; 27:259–267
65.
Bellucci DM, Glaberman K, Haslam N: Computer-assisted cognitive rehabilitation reduces negative symptoms in the severely mentally ill. Schizophr Res 2002; 59:225–232
66.
van der Gaag M, Kern RS, van den Bosch RJ, Liberman RP: A controlled trial of cognitive remediation in schizophrenia. Schizophr Bull 2002; 28:167–176
67.
López-Luengo B, Vázquez C: Effects of attention process training on cognitive functioning of schizophrenic patients. Psychiatry Res 2003; 119:41–53
68.
Hogarty GE, Flesher S, Ulrich R, Carter M, Greenwald D, Pogue-Geile M, Kechavan M, Cooley S, DiBarry AL, Garrett A, Parepally H, Zoretich R: Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior. Arch Gen Psychiatry 2004; 61:866–876
69.
Hogarty GE, Greenwald DP, Eack SM: Durability and mechanism of effects of cognitive enhancement therapy. Psychiatr Serv 2006; 57:1751–1757
70.
Ueland T, Rund BR: Cognitive remediation for adolescents with early onset psychosis: a 1-year follow-up study. Acta Psychiatr Scand 2005; 111:193–201
71.
Silverstein SM, Hatashita-Wong M, Solak BA, Uhlhaas P, Landa Y, Wilkniss SM, Goicochea C, Carpiniello K, Schenkel LS, Savitz A, Smith TE: Effectiveness of a two-phase cognitive rehabilitation intervention for severely impaired schizophrenia patients. Psychol Med 2005; 35:829–837
72.
Vauth R, Corrigan PW, Clauss M, Dietl M, Dreher-Rudolph M, Stieglitz R-D, Vater R: Cognitive strategies versus self-management skills as adjunct to vocational rehabilitation. Schizophr Bull 2005; 31:55–66
73.
Wölwer W, Frommann N, Halfmann S, Piaszek A, Streit M, Gaebel W: Remediation of impairments in facial affect recognition in schizophrenia: efficacy and specificity of a new training program. Schizophr Res 2005; 80:295–303
74.
Penades R, Catalan R, Salamero M, Boget T, Puig O, Guarch J, Gasto C: Cognitive remediation therapy for outpatients with chronic schizophrenia: a controlled and randomized study. Schizophr Res 2006; 87:323–331
75.
Bell MD, Zito W, Greig T, Wexler BE: Neurocognitive enhancement therapy with vocational services: work outcomes at two-year follow-up. Schizophr Res 2008; 105:18–29
76.
Greig TC, Zito W, Wexler BE, Fiszdon J, Bell MD: Improved cognitive function in schizophrenia after one year of cognitive training and vocational services. Schizophr Res 2007; 96:156–161
77.
Kurtz MM, Seltzer JC, Shagan DS, Thime WR, Wexler BE: Computer-assisted cognitive remediation in schizophrenia: what is the active ingredient? Schizophr Res 2007; 89:251–260
78.
Hodge MA, Siciliano D, Withey P, Moss B, Moore G, Judd G, Shores EA, Harris A: A randomized controlled trial of cognitive remediation in schizophrenia. Schizophr Bull 2010; 36:419–427
79.
Twamley EW, Savla GN, Zurhellen CH, Heaton RK: Development and pilot testing of a novel compensatory cognitive training intervention for people with psychosis. Am J Psychiatr Rehab 2008; 11:144–163
80.
Cavallaro R, Anselmetti S, Poletti S, Bechi M, Ermoli E, Cocchi F, Stratta P, Vita A, Rossi A, Smeraldi E: Computer-aided neurocognitive remediation as an enhancing strategy for schizophrenia rehabilitation. Psychiatry Res 2009; 169:191–196
81.
Kern RS, Liberman RP, Becker DR, Drake RE, Sugar CA, Green MF: Errorless learning for training individuals with schizophrenia at a community mental health setting providing work experience. Schizophr Bull 2009; 35:807–815
82.
Lindenmayer J-P, McGurk SR, Mueser KT, Khan A, Wance D, Hoffman L, Wolfe R, Xie H: A randomized controlled trial of cognitive remediation among inpatients with persistent mental illness. Psychiatr Serv 2008; 59:241–247
83.
Silverstein SM, Spaulding WD, Menditto AA, Savitz A, Liberman RP, Berten S, Starobin H: Attention shaping: a reward-based learning method to enhance skills training outcomes in schizophrenia. Schizophr Bull 2009; 35:222–232
84.
Fisher M, Holland C, Subramaniam K, Vinogradov S: Neuroplasticity-based cognitive training in schizophrenia: an interim report on the effects 6 months later. Schizophr Bull 2010; 36:869–879
85.
Eack SM, Greenwald DP, Hogarty SS, Cooley SJ, DiBarry AL, Montrose DM, Keshavan MS: Cognitive enhancement therapy for early-course schizophrenia: effects of a two-year randomized controlled trial. Psychiatr Serv 2009; 60:1468–1476
Information & Authors
Information
Published In
History
Received: 16 June 2010
Revision received: 13 October 2010
Accepted: 8 November 2010
Published online: 1 May 2011
Published in print: May 2011
Authors
Funding Information
Dr. Cellard has received funding from the Canadian Institutes of Health Research. All other authors report no financial relationships with commercial interests.Supported by the National Institute for Health Research (NIHR) Specialist Biomedical Research Centre for Mental Health Award to the South London and Maudsley National Health Service Foundation Trust, and the Institute of Psychiatry, King's College London.
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBGet Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).